Table of Contents
Chapter 1
- RENDERING LIVING OBJECTS BY INVISIBLE PROPERTIES: THE TECHNOLOGIES OF
BIOIMAGING
- 1.1. Mapping Signals from Molecular Responses and Interactions
- Three Dimensions Compressed into Two
- Tomography: Virtual Slicing and Reconstruction
- Three-Dimensional Reconstruction and Rendering of Tomographic Images
- 1.2. Computed X-ray Tomography
- 1.3. Magnetic Resonance Imaging
- 1.4. Isotope Imaging: PET and SPECT
- Single-Photon Emission Computed Tomography
- Positron Emission Tomography
- 1.5. Optical Techniques: Fluorescence, Bioluminescence, and Optical PET
- Fluorescence and Bioluminescence-Base Imaging
- Diffuse Optical Imaging
- Optical Coherence Tomography
- Confocal Laser Scanning Microscopy and Its Derivatives
- Spectroscopic Imaging Technologies
- Optical Spectroscopy
- Imaging Based on Multichannel Near-Infrared Spectroscopy
- FRAP and FLIP
- 1.6. Other Imaging Technologies and Overarching Approaches
- Ultrasound and Photoacoustics
- Imaging and Nanotechnology
- Brain Mapping with Endogenous Fields and Electrodes
Chapter 2
- MOLECULAR IMAGING IN TRANSLATIONAL RESEARCH
- 2.1. Optical Molecular Imaging Tags: From Discovery to Design
- Fluorescent Proteins
- Bioluminescence
- Target-Activated Probes and Proximity Assays
- Quantum Dots
- 2.2. Cellular-Level Molecular Imaging in Drug Discovery and Target
Characterization
- Cell-Based High-Content Screening Versus Cellular Molecular Imaging
- 2.3. Small Animal Imaging
- The SAIR Program in the United States, and Other Significant Small
Animal Imaging Sites
- Classical Microtomographic Technologies
- Optical Imaging of Laboratory Animals
- Ultrasound Imaging of Research Animals
- 2.4. Molecular Imaging Applications in Predictive Safety Technologies
- 2.5. Imaging in Clinical Trials: Present and Near Future
- A Catalog for Potential Clinical Imaging Biomarkers
- Science and Logistics: Formidable Challenges for Sponsors and Sites
- Alzheimer' s Disease
- Multiple Sclerosis
- Molecular Imaging in Cancer Trials: A Large Field Still to be Explored
- Stem Cell and Gene Therapies
- Atherosclerosis
Chapter 3
- DIAGNOSTIC IMAGING AT NUCLEAR MEDICINE CENTERS AND AT THE DOCTOR' S OFFICE
- 3.1. Key Market Characteristics for Clinical Nuclear Medicine Imaging
- 3.2. Cancer Staging, Therapy Planning, and Response Assessment
- Solid Tumors: The Largest Field for Imaging
- Lung Cancer
- Optical Breast Imaging: Beyond Digital Mammography
- Urological Cancers: Prostate and Bladder Tumors
- Melanoma
- Limited Potential for Molecular Imaging in Difficult-to-Treat Cancers
- New Developments in Colonoscopy
- 3.3. Cardiorespiratory and Vascular Imaging
- Inflammatory Lung Diseases
- Imaging Agents for Cardiac Stress Testing and Heart Failure
- Nuclear Imaging of Atherosclerotic Plaque
- 3.4. Neuroimaging
- Dementia
- Parkinson' s Disease and Attention Deficit Disorder
- Multiple Sclerosis
- Pain and Inflammation
- 3.5. Imaging in Eye Diseases
- 3.6. Arthritis, Osteoarthritis, and Gout: From Structure to Function
- 3.7. Diabetes: A Challenging Crossover Case for Molecular Imaging
- 3.8. HIV Tropism: A Clniical Application of Cellular Molecular Imaging
Chapter 4
- MOLECULAR IMAGING AND REGULATORY AUTHORITIES
- 4.1. FDA Regulations of Medical Imaging Agents
- 4.2. Specific FDA Regulations of PET Tracers
- 4.3. Molecular Imaging Feels the Crunch from the Deficit Reduction Act
Reimbursement Cut
- 4.4. Regulation of Tomographic Scanners and Picture Archiving Systems
- Tomographic Scanners
- Picture Archiving Systems
- 4.5. Molecular Imaging Data as Endpoints in Drug Trials
- Reading of Imaging Data in Clinical Trials
- Training of Readers
- Blinding of Readers
- Submission and Regulatory Review of Imaging Data
- 4.6. European Regulatory Positions on Molecular Imaging
Chapter 5
- SELECTED PLAYERS IN THE MOLECULAR IMAGING BUSINESS
- 5.1. Cellular Imaging Equipment and Software Vendors
- Carl Zeiss
- ApoTome Imaging System
- Cell Observer HS
- Laser Scanning Microscopes
- Leitz
- Total Internal Fluorescence Microscopy System
- "Super-resolution" Confocal/Multiphoton Systems
- Olympus
- Nikon
- PerkinElmer
- Caliper Life Sciences
- VisEn Medical
- Mauna Kea/Cellvizio
- VisualSonics
- Media Cybernetics
- 5.2. Manufacturing of Preclinical and Clinical Molecular Imaging Equipment
- GE Healthcare
- Siemens Healthcare
- Philips Healthcare
- Bruker
- Biospace Lab
- Berthold Technologies
- Positron
- Digirad
- Carestream Health
- LI-COR Biosciences
- 5.3. Developers of Imaging Agents and Probes
- Bayer Schering Pharma
- Siemens Medical Solutions
- GE Healthcare
- Lantheus Medical Imaging
- Alseres Pharmaceuticals
- Aposense
- Avid Radiopharmaceuticals
- Kereos
- Molecular Insight Pharmaceuticals
- FluoroPharma
- Invitrogen
- Advanced Research Technologies
- AION Diagnostics
Chapter 6
- CELLULAR MOLECULAR IMAGING, CLINICAL BIOMARKERS, AND IMAGE ANALYSIS: A
PERSPECTIVE FOR THE 2010s
- 6.1. Role of Cellular Imaging in Drug Discovery and Development
- 6.2. Imaging Biomarkers
- 6.3. Information Technology and Imaging: The Overarching Tool
Appendix A
- MOLECULAR IMAGING RESOURCES
- Societies, Transnational Institutions, and Conferences
- Journals and Databases
- Industry Magazines
- Databases
Appendix B
- INSIGHT PHARMA REPORTS MOLECULAR IMAGING SURVEY - NOVEMBER 2008
References
- Company Index with Web Addresses
|
Related Report
|
View Cart
